Haiping Dai

1.9k total citations · 1 hit paper
78 papers, 978 citations indexed

About

Haiping Dai is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Haiping Dai has authored 78 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 29 papers in Oncology and 25 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Haiping Dai's work include Acute Myeloid Leukemia Research (32 papers), CAR-T cell therapy research (27 papers) and Acute Lymphoblastic Leukemia research (25 papers). Haiping Dai is often cited by papers focused on Acute Myeloid Leukemia Research (32 papers), CAR-T cell therapy research (27 papers) and Acute Lymphoblastic Leukemia research (25 papers). Haiping Dai collaborates with scholars based in China, United States and Germany. Haiping Dai's co-authors include Depei Wu, Xiaowen Tang, Xiaming Zhu, Jia Yin, Mingqing Zhu, Zheng Li, Guanghua Chen, Ting Xu, Fengtao You and Lin Yang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Haiping Dai

67 papers receiving 969 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

2018 356 citations Xiaowen Tang, Zheng Li et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haiping Dai China	13	541	426	296	284	126	78	978
Jacob T. Jackson Australia	20	640 1.2×	722 1.7×	389 1.3×	139 0.5×	184 1.5×	36	1.3k
David Darling United Kingdom	16	211 0.4×	451 1.1×	372 1.3×	193 0.7×	168 1.3×	37	898
Ivan V. Zvyagin Russia	17	406 0.8×	1.2k 2.9×	560 1.9×	143 0.5×	86 0.7×	40	1.8k
Alyssa Sheih United States	9	440 0.8×	233 0.5×	217 0.7×	57 0.2×	136 1.1×	21	699
Tolga Sütlü Sweden	15	596 1.1×	739 1.7×	430 1.5×	220 0.8×	137 1.1×	27	1.2k
Purificación Catalina Spain	18	167 0.3×	68 0.2×	630 2.1×	151 0.5×	90 0.7×	31	997
Wooseok Seo Japan	17	183 0.3×	497 1.2×	336 1.1×	105 0.4×	54 0.4×	28	851
Steve Burke United States	9	437 0.8×	352 0.8×	281 0.9×	66 0.2×	56 0.4×	15	832
Louis van de Locht Netherlands	7	160 0.3×	117 0.3×	388 1.3×	191 0.7×	57 0.5×	9	641
Shan He China	18	184 0.3×	554 1.3×	430 1.5×	151 0.5×	51 0.4×	48	1.0k

Countries citing papers authored by Haiping Dai

Since Specialization

Citations

This map shows the geographic impact of Haiping Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiping Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiping Dai more than expected).

Fields of papers citing papers by Haiping Dai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiping Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiping Dai. The network helps show where Haiping Dai may publish in the future.

Co-authorship network of co-authors of Haiping Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Haiping Dai. A scholar is included among the top collaborators of Haiping Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiping Dai. Haiping Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Miao, Hao Zhang, Chunyan Chen, et al.. (2024). Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML. Blood. 144(Supplement 1). 1507–1507. 1 indexed citations

Li, Huiying, Qiao‐Cheng Qiu, Zheng Li, et al.. (2024). Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements. Annals of Hematology. 103(10). 4155–4161. 2 indexed citations

Liu, Yuqing, et al.. (2024). Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification. Blood. 144(Supplement 1). 1527–1527. 1 indexed citations

Qiu, Qiao‐Cheng, Man Wang, Hongjie Shen, et al.. (2023). Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review. Annals of Hematology. 102(9). 2397–2402. 4 indexed citations

Qiu, Qiao‐Cheng, Haiping Dai, Jiahui Du, et al.. (2023). Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy. British Journal of Haematology. 202(3). 539–549. 12 indexed citations

Li, Yanyan, Chongsheng Qian, Haixia Zhou, et al.. (2023). Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy. SHILAP Revista de lepidopterología. 11(12). e8289–e8289. 2 indexed citations

Dai, Haiping, et al.. (2023). Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. Annals of Hematology. 102(8). 2001–2013. 11 indexed citations

Gu, Jingxian, Sining Liu, Wei Cui, et al.. (2022). Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy. Frontiers in Immunology. 13. 858590–858590. 6 indexed citations

Zhang, Ying, Jiaqi Li, Xiaoyan Lou, et al.. (2021). A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. Frontiers in Oncology. 11. 664421–664421. 35 indexed citations

10.

Zhang, Xinyue, et al.. (2021). MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation. OncoTargets and Therapy. Volume 14. 5197–5204. 2 indexed citations

11.

Wang, Qian, Ling Zhang, Mingqing Zhu, et al.. (2021). A Recurrent Cryptic MED14-HOXA9 Rearrangement in an Adult Patient With Mixed-Phenotype Acute Leukemia, T/myeloid, NOS. Frontiers in Oncology. 11. 690218–690218. 1 indexed citations

12.

Kang, Liqing, Xiaowen Tang, Jian Zhang, et al.. (2020). Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes. Experimental Hematology and Oncology. 9(1). 11–11. 49 indexed citations

13.

Liu, Kai‐Yan, Depei Wu, Junmin Li, et al.. (2020). Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection. Advances in Therapy. 37(5). 2493–2506. 5 indexed citations

14.

Tang, Xiaowen, Zheng Li, Ting Xu, et al.. (2017). MVP Combined with FC As Lymphocyte-Depleting Chemotherapy before CAR-T Treatment Can Reduce the Incidence of Severe Cytokine Release Syndrome for Relapsed/Refractory ALL Patients with High Tumour Burden. Blood. 130. 5041–5041.

15.

Chen, Suning, Stefan Nagel, Björn Schneider, et al.. (2017). A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report. Cellular Oncology. 41(1). 93–101. 18 indexed citations

16.

Shen, Hongjie, Xinliang Mao, Haiping Dai, et al.. (2017). FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation. International Journal of Hematology. 106(4). 552–561. 20 indexed citations

17.

Dai, Haiping, Stefan Ehrentraut, Stefan Nagel, et al.. (2015). Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines. PLoS ONE. 10(11). e0139663–e0139663. 17 indexed citations

18.

Dai, Haiping, Yongquan Xue, Jianwei Zhou, et al.. (2009). LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation. Genes Chromosomes and Cancer. 48(12). 1027–1036. 9 indexed citations

19.

Qiu, Huiying, Yongquan Xue, Jun Zhang, et al.. (2008). Establishment and characterization of a new human acute myelocytic leukemia cell line SH-2 with a loss of Y chromosome, a derivative chromosome 16 resulting from an unbalanced translocation between chromosomes 16 and 17, monosomy 17, trisomy 19, and p53 alteration. Experimental Hematology. 36(11). 1487–1495. 4 indexed citations

20.

Dai, Haiping, Yongquan Xue, Jun Zhang, et al.. (2008). Translocation t(2;8)(p12;q24) in Two Patients with B Cell Chronic Lymphocytic Leukemia. Acta Haematologica. 120(4). 232–236. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact